Sponsor: Alliance Charitable Foundation
Sponsor Study ID: A012301
Study Title: A012301: LoTam: A Randomized, Phase III Clinical Trial of LowDose Tamoxifen for Selected Patients with Molecular Low-risk EarlyStage Breast Cancer
CTO #: 104192
NCT Number: NCT06671912
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Breast
Study Objectives: To evaluate whether the recurrence-free interval (RFI) with low-dose tamoxifen is non-inferior to standard-of-care endocrine therapy among post-menopausal women with early-stage, low molecular risk breast cancer.